Involvement of spinal tyrosine kinase in inflammatory and N-methyl-D-aspartate-induced hyperalgesia in ratsSATO, Eiru; TAKANO, Yoshito; KUNO, Yuichiro et al.European journal of pharmacology. 2003, Vol 468, Num 3, pp 191-198, issn 0014-2999, 8 p.Article

Third-Generation Tyrosine Kinase Inhibitors and BeyondQUINTAS-CARDAMA, Alfonso; KANTARJIAN, Hagop; CORTES, Jorge et al.Seminars in hematology. 2010, Vol 47, Num 4, pp 371-380, issn 0037-1963, 10 p.Article

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesLOVLY, Christine M; SHAW, Alice T.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2249-2256, issn 1078-0432, 8 p.Article

Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorBLAY, Jean-Yves; VON MEHREN, Margaret.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S3-S9, SUP1Article

NilotinibDEININGER, Michael W.Clinical cancer research. 2008, Vol 14, Num 13, pp 4027-4031, issn 1078-0432, 5 p.Article

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumorsOCHS, Judith S.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 3, pp 941-949, issn 0360-3016, 9 p.Conference Paper

Tyrosine kinase inhibitor STI-571/gleevec down-regulates the β-catenin signaling activityLAN ZHOU; AN, Naili; JAE YOON PARKA et al.Cancer letters. 2003, Vol 193, Num 2, pp 161-170, issn 0304-3835, 10 p.Article

Morphological and Hydrodynamic Correlations with Increasing Outflow Facility by Rho-Kinase Inhibitor Y-27632HAIYAN GONG; YANG, Chen-Yuan Charlie.Journal of ocular pharmacology and therapeutics. 2014, Vol 30, Num 2-3, pp 143-153, issn 1080-7683, 11 p.Conference Paper

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107VON BUBNOFF, N; GORANTLA, S. H. P; KANCHA, R. K et al.Leukemia. 2005, Vol 19, Num 9, pp 1670-1671, issn 0887-6924, 2 p.Article

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsBIANCO, Roberto; INCHEOL SHIN; RITTER, Christoph A et al.Oncogene (Basingstoke). 2003, Vol 22, Num 18, pp 2812-2822, issn 0950-9232, 11 p.Article

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cellsLANXI SONG; TURKSON, James; KARRAS, James G et al.Oncogene (Basingstoke). 2003, Vol 22, Num 27, pp 4150-4165, issn 0950-9232, 16 p.Article

Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agentYANTING ZHANG; YAQIONG ZHANG; SHENGRONG GUO et al.International journal of pharmaceutics (Print). 2009, Vol 369, Num 1-2, pp 19-23, issn 0378-5173, 5 p.Article

Pazopanib: Clinical development of a potent anti-angiogenic drugSCHUTZ, Fabio A. B; CHOUEIRI, Toni K; STERNBERG, Cora N et al.Critical reviews in oncology/hematology. 2011, Vol 77, Num 3, pp 163-171, issn 1040-8428, 9 p.Article

Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemiaMIZUTANI, Shinsuke; KURODA, Junya; SHIMIZU, Daisuke et al.International journal of hematology. 2010, Vol 91, Num 3, pp 516-521, issn 0925-5710, 6 p.Article

Inhibitory effect of tyrphostin 47 on Shiga toxin-induced cell deathIKEDA, Masahiro; GUNJI, Yasuhiro; SONODA, Hiroko et al.European journal of pharmacology. 2006, Vol 546, Num 1-3, pp 36-39, issn 0014-2999, 4 p.Article

Inhibition of Kv4.3 by genistein via a tyrosine phosphorylation-independent mechanismHEE JAE KIM; HYE SOOK AHN; BOK HEE CHOI et al.American journal of physiology. Cell physiology. 2011, Vol 69, Num 3, issn 0363-6143, C567-C575Article

The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine TumorsLEI YE; SANTARPIA, Libero; GAGEL, Robert F et al.Endocrine reviews. 2010, Vol 31, Num 4, pp 578-599, issn 0163-769X, 22 p.Article

Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor ComplexBEEVERS, Christopher S; LONG CHEN; LEI LIU et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 3, pp 1000-1008, issn 0008-5472, 9 p.Article

Nilotinib. CommentariesROSTI, Gianantonio; LE COUTRE, Philipp.Drugs (Basel). 2008, Vol 68, Num 4, pp 460-461, issn 0012-6667, 2 p.Article

Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii InfectionSTONE DOGGETT, J; OJO, Kayode K; FAN, Erkang et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 6, pp 3547-3549, issn 0066-4804, 3 p.Article

Thyroid effects of tyrosine kinase inhibitorsILLOUZ, Frédéric; BRAUN, Doreen; BRIET, Claire et al.European journal of endocrinology. 2014, Vol 171, Num 3, issn 0804-4643, R91-R99Article

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentSTROBER, B; BUONANNO, M; PAPP, K et al.British journal of dermatology (1951). 2013, Vol 169, Num 5, pp 992-999, issn 0007-0963, 8 p.Article

Binding of curcumin to β-lactoglobulin and its effect on antioxidant characteristics of curcuminMING LI; YING MA; NGADI, Michael O et al.Food chemistry. 2013, Vol 141, Num 2, pp 1504-1511, issn 0308-8146, 8 p.Article

Curcumin Eliminates Leptin's Effects on Hepatic Stellate Cell Activation via Interrupting Leptin SignalingYOUCAI TANG; SHIZHONG ZHENG; ANPING CHEN et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 7, pp 3011-3020, issn 0013-7227, 10 p.Article

Dosage plasrnatique des inhibiteurs de tyrosine kinaseBOUCHET, S; POULETTE, S; MOLIMARD, M et al.Correspondances en onco-hématologie. 2009, Vol 4, Num 4, pp 177-178, issn 1954-4820, 2 p.Article